Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
GPCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.33 - $62.74
Previous CloseN/A
Volume219.80K
Average Volume (3M)813.40K
Market Cap
$1.30B
Enterprise Value$1.60B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 27, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding57,260,674
10 Day Avg. Volume786,757
30 Day Avg. Volume813,402
Standard Deviation0.25
R-Squared0.16
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)70.42
Price to Cash Flow (P/CF)-17.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.69K
Enterprise Value/Ebitda-11.32
Forecast
1Y Price Target
$79.33Price Target Upside239.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Structure Therapeutics, Inc. Sponsored ADR News
PremiumCompany Announcements
Structure Therapeutics Advances Obesity Treatment Candidate
PremiumStock Analysis & Ideas
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Structure Therapeutics Reports Strong Q3 2024 Results---
Bulls Say, Bears Say
Bulls Say
Market PositionGPCR has one of the broadest obesity pipelines and is solidifying its position as the leading small molecule player.
Research And DevelopmentGPCR is starting its Phase 1 trial of ACCG-2671 and will have the first-in human data, indicating progress in their research and development pipeline.
Bears Say
Tolerability IssuesTolerability remains a critical issue for GSBR-1290, with nausea rates of 70–84% and vomiting in 40–63% of participants, which may challenge compliance and limit broad adoption.
---
Ownership Overview
10.34% Insiders
39.22% Mutual Funds
<0.01% Other Institutional Investors
49.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $22.33 and its highest was $62.74 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.30B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.182 by -$0.018.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.22.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,260,674 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.182. Following the earnings report the stock price went up 3.629%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.33 (239.16% Upside)
$79.33 (239.16% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.06%
12-Months-Change
Fundamentals
Return on Equity
-20.36%
Trailing 12-Months
Asset Growth
331.31%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Month Forecast
Average Price Target
$79.33
▲(239.16% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
+4.31%
reiterated a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +4.31% per trade.
---